Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia

Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies

(2014) José O Alemán et al.   ENDOCRINE-RELATED CANCER

Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia

(2014) D. Rea et al.   HAEMATOLOGICA

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

(2013) E. Jabbour et al.   BLOOD

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia

(2013) Z. Racil et al.   HAEMATOLOGICA

Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience

(2013) V. Brazzelli et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis

(2013) Karthik R. Narayanan et al.   PEDIATRIC BLOOD & CANCER

Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors

(2013) Gabriele Gugliotta et al.   Expert Review of Hematology

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

(2012) Xuelin Huang et al.   CANCER

Pulmonary Arterial Hypertension in Patients Treated by Dasatinib

(2012) David Montani et al.   CIRCULATION

Drug induced rhabdomyolysis

(2012) Martin Hohenegger   CURRENT OPINION IN PHARMACOLOGY

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

(2012) Roberto Latagliata et al.   HEMATOLOGICAL ONCOLOGY

Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index

(2012) Massimo Breccia et al.   LEUKEMIA RESEARCH

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

(2011) Karl J. Aichberger et al.   AMERICAN JOURNAL OF HEMATOLOGY

Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients

(2011) M. S. Marcolino et al.   ANNALS OF ONCOLOGY

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

(2011) J. E. Cortes et al.   BLOOD

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

(2011) J. E. Cortes et al.   BLOOD

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

(2011) H. M. Kantarjian et al.   BLOOD

Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML

(2011) Gianantonio Rosti et al.   CANCER TREATMENT REVIEWS

Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib

(2011) IRIS AMITAY-LAISH et al.   Dermatologic Therapy

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

(2011) Carlo Gambacorti-Passerini et al.   JNCI-Journal of the National Cancer Institute

Severe Peripheral Arterial Disease During Nilotinib Therapy

(2011) P. Le Coutre et al.   JNCI-Journal of the National Cancer Institute

Cardiovascular toxicity of anti-angiogenic drugs

(2011) Gaetan des Guetz et al.   Targeted Oncology

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

(2010) H. M. Kantarjian et al.   BLOOD

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

(2010) N. P. Shah et al.   HAEMATOLOGICA

Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

(2010) Wei-Sheng Huang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

(2010) Theo D. Kim et al.   THYROID

Dasatinib-Induced Pleural Effusions: A Lymphatic Network Disorder?

(2009) Mark Goldblatt et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

(2009) A. Quintas-Cardama et al.   BLOOD

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy

(2009) Alfonso Quintás-Cardama et al.   CANCER

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

(2009) Kimmo Porkka et al.   CANCER

Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

(2009) C Tanaka et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure

(2009) F. Palandri et al.   HAEMATOLOGICA

Decreased Bone Turnover Despite Persistent Secondary Hyperparathyroidism during Prolonged Treatment with Imatinib

(2009) Susannah O'Sullivan et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis

(2008) Hugues de Lavallade et al.   BRITISH JOURNAL OF HAEMATOLOGY

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

(2008) Neil P. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

(2008) L L Remsing Rix et al.   LEUKEMIA

Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience

(2007) Massimo Breccia et al.   LEUKEMIA RESEARCH